S&P 500   2,690.64 (+1.01%)
DOW   22,956.43 (+1.22%)
QQQ   197.94 (+0.74%)
AAPL   261.09 (-0.53%)
FB   168.49 (+1.78%)
MSFT   164.83 (-0.27%)
GOOGL   1,189.25 (+0.51%)
AMZN   2,012.46 (+0.74%)
CGC   14.55 (+1.39%)
NVDA   259.33 (-3.38%)
BABA   198.30 (+0.94%)
MU   46.54 (+0.37%)
GE   7.07 (-2.35%)
TSLA   548.23 (+6.20%)
AMD   47.97 (+0.95%)
T   30.35 (+3.09%)
ACB   0.80 (+0.00%)
F   4.76 (+4.85%)
NFLX   374.06 (-1.55%)
BAC   22.26 (+4.02%)
GILD   74.90 (-3.64%)
DIS   101.24 (+1.67%)
S&P 500   2,690.64 (+1.01%)
DOW   22,956.43 (+1.22%)
QQQ   197.94 (+0.74%)
AAPL   261.09 (-0.53%)
FB   168.49 (+1.78%)
MSFT   164.83 (-0.27%)
GOOGL   1,189.25 (+0.51%)
AMZN   2,012.46 (+0.74%)
CGC   14.55 (+1.39%)
NVDA   259.33 (-3.38%)
BABA   198.30 (+0.94%)
MU   46.54 (+0.37%)
GE   7.07 (-2.35%)
TSLA   548.23 (+6.20%)
AMD   47.97 (+0.95%)
T   30.35 (+3.09%)
ACB   0.80 (+0.00%)
F   4.76 (+4.85%)
NFLX   374.06 (-1.55%)
BAC   22.26 (+4.02%)
GILD   74.90 (-3.64%)
DIS   101.24 (+1.67%)
S&P 500   2,690.64 (+1.01%)
DOW   22,956.43 (+1.22%)
QQQ   197.94 (+0.74%)
AAPL   261.09 (-0.53%)
FB   168.49 (+1.78%)
MSFT   164.83 (-0.27%)
GOOGL   1,189.25 (+0.51%)
AMZN   2,012.46 (+0.74%)
CGC   14.55 (+1.39%)
NVDA   259.33 (-3.38%)
BABA   198.30 (+0.94%)
MU   46.54 (+0.37%)
GE   7.07 (-2.35%)
TSLA   548.23 (+6.20%)
AMD   47.97 (+0.95%)
T   30.35 (+3.09%)
ACB   0.80 (+0.00%)
F   4.76 (+4.85%)
NFLX   374.06 (-1.55%)
BAC   22.26 (+4.02%)
GILD   74.90 (-3.64%)
DIS   101.24 (+1.67%)
S&P 500   2,690.64 (+1.01%)
DOW   22,956.43 (+1.22%)
QQQ   197.94 (+0.74%)
AAPL   261.09 (-0.53%)
FB   168.49 (+1.78%)
MSFT   164.83 (-0.27%)
GOOGL   1,189.25 (+0.51%)
AMZN   2,012.46 (+0.74%)
CGC   14.55 (+1.39%)
NVDA   259.33 (-3.38%)
BABA   198.30 (+0.94%)
MU   46.54 (+0.37%)
GE   7.07 (-2.35%)
TSLA   548.23 (+6.20%)
AMD   47.97 (+0.95%)
T   30.35 (+3.09%)
ACB   0.80 (+0.00%)
F   4.76 (+4.85%)
NFLX   374.06 (-1.55%)
BAC   22.26 (+4.02%)
GILD   74.90 (-3.64%)
DIS   101.24 (+1.67%)
Log in

NASDAQ:PRTKParatek Pharmaceuticals Stock Price, Forecast & News

$4.07
+0.22 (+5.71 %)
(As of 04/7/2020 03:11 PM ET)
Add
Compare
Today's Range
$3.67
Now: $4.07
$4.15
50-Day Range
$2.67
MA: $3.61
$4.97
52-Week Range
$2.50
Now: $4.07
$6.39
Volume436,083 shs
Average Volume860,517 shs
Market Capitalization$171.84 million
P/E RatioN/A
Dividend YieldN/A
Beta1.35
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
Read More
Paratek Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.42 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:PRTK
Previous SymbolNASDAQ:TSPT
CUSIP89354M10
Phone617-807-6600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.54 million
Book Value($1.19) per share

Profitability

Net Income$-128,790,000.00
Net Margins-778.47%

Miscellaneous

Employees101
Market Cap$171.84 million
Next Earnings Date5/13/2020 (Estimated)
OptionableOptionable

Receive PRTK News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTK and its competitors with MarketBeat's FREE daily newsletter.


Paratek Pharmaceuticals (NASDAQ:PRTK) Frequently Asked Questions

How has Paratek Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Paratek Pharmaceuticals' stock was trading at $3.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PRTK shares have increased by 4.9% and is now trading at $4.08. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Paratek Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Paratek Pharmaceuticals.

When is Paratek Pharmaceuticals' next earnings date?

Paratek Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Paratek Pharmaceuticals.

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals Inc (NASDAQ:PRTK) announced its quarterly earnings data on Tuesday, February, 25th. The specialty pharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($1.03) by $0.22. The specialty pharmaceutical company had revenue of $8.97 million for the quarter, compared to analyst estimates of $4.78 million. Paratek Pharmaceuticals had a negative net margin of 778.47% and a negative return on equity of 5,327.73%. View Paratek Pharmaceuticals' earnings history.

What guidance has Paratek Pharmaceuticals issued on next quarter's earnings?

Paratek Pharmaceuticals issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, February, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $75-80 million, compared to the consensus revenue estimate of $68.08 million.

What price target have analysts set for PRTK?

7 equities research analysts have issued twelve-month target prices for Paratek Pharmaceuticals' shares. Their forecasts range from $6.00 to $36.00. On average, they anticipate Paratek Pharmaceuticals' stock price to reach $17.20 in the next twelve months. This suggests a possible upside of 321.6% from the stock's current price. View analysts' price targets for Paratek Pharmaceuticals.

Has Paratek Pharmaceuticals been receiving favorable news coverage?

Headlines about PRTK stock have trended very negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Paratek Pharmaceuticals earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned press coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutParatek Pharmaceuticals.

Who are some of Paratek Pharmaceuticals' key competitors?

What other stocks do shareholders of Paratek Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Aduro BioTech (ADRO), Verastem (VSTM), EXACT Sciences (EXAS), Exelixis (EXEL), Energy Transfer LP Unit (ET), Progenics Pharmaceuticals (PGNX), TG Therapeutics (TGTX), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD) and Inovio Pharmaceuticals (INO).

Who are Paratek Pharmaceuticals' key executives?

Paratek Pharmaceuticals' management team includes the following people:
  • Mr. Michael F. Bigham, Chairman & CEO (Age 61)
  • Dr. Evan Loh, Pres, Chief Medical Officer, COO & Director (Age 60)
  • Mr. William M. Haskel, Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 57)
  • Mr. Adam Woodrow, Chief Commercial Officer & VP (Age 52)
  • Mr. Douglas W. Pagán, Consultant (Age 47)

What is Paratek Pharmaceuticals' stock symbol?

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

How do I buy shares of Paratek Pharmaceuticals?

Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Paratek Pharmaceuticals' stock price today?

One share of PRTK stock can currently be purchased for approximately $4.08.

How big of a company is Paratek Pharmaceuticals?

Paratek Pharmaceuticals has a market capitalization of $172.26 million and generates $16.54 million in revenue each year. The specialty pharmaceutical company earns $-128,790,000.00 in net income (profit) each year or ($3.93) on an earnings per share basis. Paratek Pharmaceuticals employs 101 workers across the globe. View additional information about Paratek Pharmaceuticals.

What is Paratek Pharmaceuticals' official website?

The official website for Paratek Pharmaceuticals is http://www.paratekpharma.com/.

How can I contact Paratek Pharmaceuticals?

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected]

This page was last updated on 4/7/2020 by MarketBeat.com Staff

Featured Article: Price-Sales Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel